Advertisement
Advertisement
U.S. Markets open in 8 hrs 21 mins
Advertisement
Advertisement
Advertisement
Advertisement

Matinas BioPharma Holdings, Inc. (MTNB)

NYSE American - NYSE American Delayed Price. Currency in USD
Add to watchlist
0.8200+0.0101 (+1.25%)
At close: 04:00PM EDT
0.7998 -0.02 (-2.46%)
After hours: 07:14PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.8099
Open0.7999
Bid0.0000 x 1300
Ask0.0000 x 800
Day's Range0.7900 - 0.8300
52 Week Range0.4900 - 1.6100
Volume222,855
Avg. Volume549,470
Market Cap177.323M
Beta (5Y Monthly)2.22
PE Ratio (TTM)N/A
EPS (TTM)-0.1140
Earnings DateMar 28, 2022 - Apr 01, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.75
  • Insider Monkey

    10 Best Biotech Penny Stocks To Buy Now

    In this article, we discuss the 10 best biotech penny stocks to buy now. If you want to skip our detailed analysis of the biotech sector, go directly to 5 Best Biotech Penny Stocks To Buy Now. Like all sectors of the economy right now, the biotech sector is going through a lot of pain. The […]

  • GlobeNewswire

    Matinas BioPharma to Present at the LD Micro Invitational XII Conference

    BEDMINSTER, N.J., May 31, 2022 (GLOBE NEWSWIRE) -- Matinas BioPharma (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company focused on improving the intracellular delivery of nucleic acids and small molecules with its lipid nanocrystal (LNC) platform technology, announced today that Jerry Jabbour, Chief Executive Officer, has been invited to present at the LD Micro Invitational XII Conference on Tuesday, June 7, 2022, at 3:30 p.m. ET (12:30 p.m. PT). The conference is being held at the Fo

  • Zacks

    Matinas Biopharma Holdings, Inc. (MTNB) Reports Q1 Loss, Misses Revenue Estimates

    Matinas Biopharma Holdings, Inc. (MTNB) delivered earnings and revenue surprises of 0% and 100%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Advertisement
Advertisement